Organon & Co. (NYSE:OGN – Get Free Report) declared a quarterly dividend on Friday, October 30th. Investors of record on Monday, November 9th will be paid a dividend of $0.02 per share on Thursday, December 10th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, November 9th.
Organon & Co. has a payout ratio of 2.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $3.43 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.3%.
Organon & Co. Stock Performance
Shares of OGN stock opened at $13.84 on Friday. The firm has a market cap of $3.63 billion, a P/E ratio of 18.20, a PEG ratio of 1.27 and a beta of 1.53. The company has a debt-to-equity ratio of 7.11, a current ratio of 2.02 and a quick ratio of 1.44. The stock’s 50-day moving average is $13.75 and its two-hundred day moving average is $11.60. Organon & Co. has a fifty-two week low of $5.69 and a fifty-two week high of $13.88.
Organon & Co. (NYSE:OGN – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.58 billion. Organon & Co. had a return on equity of 82.06% and a net margin of 3.49%. Analysts predict that Organon & Co. will post 3.24 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Organon & Co. presently has an average rating of “Reduce” and an average target price of $11.40.
Check Out Our Latest Research Report on Organon & Co.
Organon & Co. Company Profile
Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.
Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.
Featured Articles
- Five stocks we like better than Organon & Co.
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
